Washington State University to review claims of research misconduct

Rhea-AI Summary

Washington State University has initiated a review of potential research misconduct claims involving former student Leen Kawas, now the CEO of Athira Pharma (NASDAQ: ATHA). The Athira board has placed Kawas on temporary leave while it conducts its own investigation into her doctoral research. WSU emphasizes its commitment to high ethical standards in research and is adhering to its Executive Policy 33 for handling such allegations. Further details will be withheld until the review is concluded.

Positive

• Athira Pharma is taking proactive measures by placing CEO Leen Kawas on leave to address the allegations.

Negative

• The investigation into research misconduct could harm Athira's reputation and investor confidence.
• Uncertainty regarding the outcome of the investigation may lead to stock volatility.

PULLMAN, Wash., June 18, 2021 /PRNewswire/ -- Washington State University announced today that it has undertaken a review of claims of potential research misconduct involving research conducted by Leen Kawas, a former WSU student and current president and chief executive officer of Athira Pharma, Inc. (NASDAQ: ATHA). On Thursday, the Athira Pharma board of directors announced that it had placed Kawas on temporary leave pending its own review of actions stemming from Kawas' doctoral research while at WSU.

Washington State University expects its researchers to adhere to the highest ethical standards in the conduct of research activities. The University takes allegations of research misconduct very seriously.  WSU is conducting its inquiry into this issue in accordance with the University's Executive Policy 33, which governs how the institution responds to allegations of research misconduct.

Washington State University will refrain from discussing the matter further until the review process is complete.

 

View original content:http://www.prnewswire.com/news-releases/washington-state-university-to-review-claims-of-research-misconduct-301315597.html

SOURCE Washington State University

FAQ

What allegations are being investigated regarding Athira Pharma's CEO?

Leen Kawas, CEO of Athira Pharma, is under investigation for potential research misconduct related to her doctoral research at Washington State University.

What actions has Athira Pharma taken in response to the allegations against its CEO?

Athira Pharma's board has placed CEO Leen Kawas on temporary leave pending a review of the allegations.

How does Washington State University handle research misconduct allegations?

WSU conducts inquiries in accordance with its Executive Policy 33, which outlines its process for responding to research misconduct.

What is the potential impact of the investigation on Athira Pharma's stock?

The investigation may negatively affect investor confidence and lead to stock volatility for Athira Pharma.